A) PBCEC: untreated control B) PBCEC: AgEO-NP 25 μg/mL C) PBCEC: AgCitrate-NP 25 μg/mL D) PCPEC: untreated control E) PCPEC: AgEO-NP 25 μg/mL F) PCPEC: AgCitrate-NP 25 μg/mL.
|
| Figure 5: Immunostaining analysis of occludin after treatment of PBCEC and PCPEC monolayers with AgEO- and AgCitrate-NPs for 24 h. A) PBCEC: untreated control B) PBCEC: AgEO-NP 25 μg/mL C) PBCEC: AgCitrate-NP 25 μg/mL D) PCPEC: untreated control E) PCPEC: AgEO-NP 25 μg/mL F) PCPEC: AgCitrate-NP 25 μg/mL. |
